{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:38:15Z","timestamp":1782970695125,"version":"3.54.5"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Secretory carcinoma of the breast (SCB) is an extremely rare malignant neoplasm, accounting for less than 0.15% of all breast carcinomas. It is characterized by distinctive secretory activity, a frequently triple-negative immunophenotype, and recurrent ETV6-NTRK3 fusion (\n                      <jats:xref>1<\/jats:xref>\n                      \u2013\n                      <jats:xref>3<\/jats:xref>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentations<\/jats:title>\n                    <jats:p>We report two Chinese women with SCB. Case 1 involved a 55-year-old woman with a 1.2-cm mass, and Case 2 involved a 43-year-old woman with a 3.8-cm mass. Both tumors showed characteristic morphology, including microcystic\/tubulocystic, solid, tubular, and focally papillary growth patterns, abundant eosinophilic secretory material, granular eosinophilic or vacuolated cytoplasm, and minimal cytologic atypia. Immunohistochemistry revealed a triple-negative phenotype (ER-negative, PR-negative, and HER2-negative) with diffuse S-100 and CK5\/6 positivity. Mammaglobin and MUC4 showed membranous positivity, whereas DOG1 was negative in tumor cells at \u00d7100 magnification. These findings provided ancillary support for secretory differentiation and helped exclude acinic cell carcinoma. AB-PAS staining showed positive intracytoplasmic secretory material in tumor cells at \u00d7200 magnification. ETV6-NTRK3 fusion was confirmed by FISH in both tumors (75% and 80% of tumor nuclei), supporting the diagnosis of SCB. Both patients underwent breast-conserving surgery. Case 1 had no nodal metastasis (0\/2; T1cN0M0, AJCC 8th edition), whereas Case 2 had sentinel lymph node metastasis (1\/3; T2N1aM0, AJCC 8th edition), followed by axillary lymph node dissection (0\/23). Both patients received adjuvant chemotherapy and radiation therapy. No locoregional recurrence or distant metastasis was observed during short-to-intermediate follow-up of 18 months in Case 1 and 30 months in Case 2. However, these observations reflect only the current clinical status of the two patients and are insufficient to support conclusions regarding long-term prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These cases highlight the diagnostic challenges of SCB and underscore the importance of integrating morphology, immunohistochemistry, and FISH-based molecular confirmation. ETV6-NTRK3 fusion may represent a potential therapeutic option only in selected patients with advanced, unresectable, recurrent, or metastatic NTRK fusion-positive disease. Neither patient in the present report had advanced disease, received TRK inhibitor therapy, or underwent functional validation of the fusion. Therefore, no conclusion regarding therapeutic efficacy can be drawn from these two localized cases. Long-term follow-up remains necessary because late recurrence and distant metastasis have been reported in the literature, and the short-to-intermediate follow-up in the present cases does not allow definitive prognostic conclusions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1883805","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:25:34Z","timestamp":1782966334000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report: Secretory carcinoma of the breast with ETV6-NTRK3 fusion: clinicopathological features and molecular confirmation by FISH in two cases"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaoyu","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Pathology, Zibo Central Hospital","place":["Zibo, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Zibo Central Hospital","place":["Zibo, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/his.14091","article-title":"The 2019 World Health Organization classification of tumours of the breast","volume":"77","author":"Tan","year":"2020","journal-title":"Histopathology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/his.12172","article-title":"Secretory carcinoma of the breast and its histopathological mimics: value of markers for differential diagnosis","volume":"63","author":"Osako","year":"2013","journal-title":"Histopathology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00180-0","article-title":"Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma","volume":"2","author":"Tognon","year":"2002","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1966.03100050096033","article-title":"Breast carcinoma in children","volume":"195","author":"McDivitt","year":"1966","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.32","article-title":"Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas","volume":"30","author":"Krings","year":"2017","journal-title":"Mod Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07153-1","article-title":"Secretory breast carcinoma: clinicopathological features and prognosis of 52 patients","volume":"203","author":"Zhao","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.190","article-title":"Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature","volume":"25","author":"Li","year":"2012","journal-title":"Mod Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2018.0035","article-title":"Clinicopathologic and molecular characteristics of 44 patients with pure secretory breast carcinoma","volume":"16","author":"Li","year":"2019","journal-title":"Cancer Biol Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13000-021-01115-1","article-title":"Secretory carcinoma of the breast with multiple distant metastases in the brain and unfavorable prognosis: a case report and literature review","volume":"16","author":"Tang","year":"2021","journal-title":"Diagn Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1641375","article-title":"Case report: Metastasis to pleura and mediastinal lymph nodes from breast secretory carcinoma: 10 years follow-up","volume":"15","author":"Huang","year":"2025","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6486-6","article-title":"Eighth edition of the AJCC cancer staging manual: breast cancer","volume":"25","author":"Giuliano","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/his.13879","article-title":"Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential","volume":"75","author":"Hoda","year":"2019","journal-title":"Histopathology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24241","article-title":"Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base","volume":"113","author":"Jacob","year":"2016","journal-title":"J Surg Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/00031348231199174","article-title":"Secretory carcinoma of breast: a population-based study","volume":"90","author":"Sanli","year":"2024","journal-title":"Am Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.13126","article-title":"Secretory breast carcinoma in an 8-year-old girl: a case report and literature review","volume":"24","author":"Garlick","year":"2018","journal-title":"Breast J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2008.184","article-title":"Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum","volume":"22","author":"Lae","year":"2009","journal-title":"Mod Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001366","article-title":"Pan-TRK immunohistochemistry: a useful diagnostic adjunct for secretory carcinoma of the breast","volume":"43","author":"Harrison","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/pin.13204","article-title":"NTRK gene fusions are detected in both secretory and non-secretory breast cancers","volume":"72","author":"Maund","year":"2022","journal-title":"Pathol Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174246","article-title":"The impact of ETV6-NTRK3 oncogenic gene fusions on molecular and signaling pathway alterations","volume":"15","author":"Kinnunen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.29011\/2574-710X.10323","article-title":"RNA sequencing yields actionable markers in a rare case of pediatric male secretory breast carcinoma","volume":"11","author":"Guha","year":"2026","journal-title":"J Oncol Res Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.10.012","article-title":"Acinic cell carcinoma of the breast: a comprehensive review","volume":"66","author":"Ajkunic","year":"2022","journal-title":"Breast"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/path.4691","article-title":"Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations","volume":"238","author":"Guerini-Rocco","year":"2016","journal-title":"J Pathol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.17305\/bjbms.2016.1811","article-title":"Apocrine carcinoma of the breast: a brief update on the molecular features and targetable biomarkers","volume":"17","author":"Vranic","year":"2017","journal-title":"Bosn J Basic Med Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/path.5006","article-title":"MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene","volume":"244","author":"Kim","year":"2018","journal-title":"J Pathol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/tbcr-24-31","article-title":"Chinese society of clinical oncology (CSCO) breast cancer guidelines 2024","volume":"5","author":"Li","year":"2024","journal-title":"Transl Breast Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1883805\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:25:37Z","timestamp":1782966337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1883805\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":28,"alternative-id":["10.3389\/fonc.2026.1883805"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1883805","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1883805"}}